Sugi Predict

Sugi Predict / Compounds / SCHEMBL3050557

SCHEMBL3050557

SCHEMBL3050557

CCC(=O)O[C@@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR3C2 P08235 8/20 1.00
▸ PGR P06401 4/20 0.87
▸ NR3C1 P04150 3/20 0.87
▸ HIF1A Q16665 8/20 0.86
▸ KMT2A Q03164 2/20 0.86
▸ AR P10275 3/20 0.81
▸ CHRM1 P11229 2/20 0.81
▸ SMN1; SMN2 Q16637 3/20 0.70
▸ CYP2C19 P33261 2/20 0.70
▸ HSD17B10 Q99714 2/20 0.70
▸ SERPINA6 P08185 2/20 0.70
▸ MAPT P10636 2/20 0.70
▸ SHBG P04278 1/20 0.70
▸ CYP3A4 P08684 1/20 0.70
▸ NFKB1 P19838 1/20 0.70
▸ LMNA P02545 2/20 0.60
▸ POLB P06746 1/20 0.58
▸ GAA P10253 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL180224 1.00 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL14936105 1.00 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL11618795 0.94 NR3C2 (0.88) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL11618797 0.94 NR3C2 (0.88) NR3C2PGRNR3C1HIF1AKMT2A
SCHEMBL11751119 0.94 NR3C2 (0.88) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL111478 0.93 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL14936050 0.93 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL21111521 0.93 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL4695 0.93 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A
Hydrocortisone Butyrate SCHEMBL14339600 0.93 NR3C2 (1.00) NR3C2PGRNR3C1HIF1AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9956144-B2 Process for particle processing of active pharmaceutical ingredients HOVIONE INTER LIMITED (CH) 2018-05-01 — — US claimed
US-20130203717-A1 Process for Particle Processing of Active Pharmaceutical Ingredients HOVIONE INTER LTD (CH) 2013-08-08 — — US claimed
US-20080038219-A1 Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof CALGENEX CORPORATION (US) 2008-02-14 — — US claimed
US-20070184114-A1 Formulation for topical non-invasive application in vivo IDEA AG (DE) 2007-08-09 — — US claimed
CN-1320880-C Improved formulation for topical non-invasive application in vivo IDEA INNOVAT DERMALE APPL GMBH (DE) 2007-06-13 — — CN claimed
US-7175850-B2 Formulation for topical non-invasive application in vivo IDEA AG (DE) 2007-02-13 — — US claimed
EP-1140021-B1 IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO IDEA AG (DE) 2004-08-04 — — EP claimed
JP-2002533379-A — — 2002-10-08 — — JP claimed
US-20020064524-A1 Formulation for topical non-invasive application in vivo IDEA AG (DE) 2002-05-30 — — US claimed
CN-1327382-A Improved formulation for topical non-invasive application in vivo IDEA INNOVAT DERMALE APPL GMBH (DE) 2001-12-19 — — CN claimed
EP-1140021-A1 IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO IDEA AG (DE) 2001-10-10 — — EP claimed
WO-2000038653-A1 IMPROVED FORMULATION FOR TOPICAL NON-INVASIVE APPLICATION IN VIVO IDEA AG. (DE) 2000-07-06 — — WO claimed
EP-0217141-B1 W/O CREAMS CONTAINING 17-PROPIONATE-21-ACETATE Beiersdorf Aktiengesellschaft (DE) 1990-09-26 — — EP claimed
EP-0217146-B1 W/O CREAMS CONTAINING HYDROCORTISONE DIESTERS Beiersdorf Aktiengesellschaft (DE) 1990-09-12 — — EP claimed
US-4902682-A W/O cream containing hydrocortisone diester BEIERSDORF AG (DE) 1990-02-20 — — US claimed
EP-2560620-B1 A PROCESS FOR PARTICLE PROCESSING OF ACTIVE PHARMACEUTICAL INGREDIENTS HOVIONE INT LTD (CH) 2020-09-16 — — EP disclosed
US-10328027-B2 Assisted particle size reduction process HOVIONE INTERNATIONAL LTD. (HK) 2019-06-25 — — US disclosed
EP-0217146-B1 W/O CREAMS CONTAINING HYDROCORTISONE DIESTERS Beiersdorf Aktiengesellschaft (DE) 1990-09-12 — — EP disclosed
US-4902682-A W/O cream containing hydrocortisone diester BEIERSDORF AG (DE) 1990-02-20 — — US disclosed
US-4113680-A Method for preparing 17 α-ester-21-halo pregnanes TAISHO PHARMACEUTICAL CO., LTD. (JP) 1978-09-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020064524-A1 Formulation for topical non-invasive application in vivo CUTA, LPO, GPX4 NR3C2 4838/4885PGR 3545/4885NR3C1 4660/4885
US-20070184114-A1 Formulation for topical non-invasive application in vivo GPX4, LPO, MMP8 NR3C2 4659/4885PGR 2277/4885NR3C1 4351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.